Findings from the CheckMate 274 study, a phase III, multi centre, double-blind randomized trial determining the efficacy of adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma was recently published by Memorial Sloan Kettering Cancer Centre in New York. While study investigators plan additional follow-up to assess overall survival, study results have shown that disease-free-survival "was longer with adjuvant nivolumab than with placebo in the ITT population."
To read more about this study, click here.
Source mentioned: Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021;384:2102-2114. DOI: 10.1056/NEJMoa2034442.
No comments:
Post a Comment